SI-BONE, Inc. (SIBN), a medical device firm, on Tuesday said that it will report fourth-quarter and full-year results after market close on February 23, and will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
SI-BONE focuses on solutions to musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally.
In January, SI-BONE reported preliminary revenue growth of 15% revenue for the fourth quarter and a 20% increase in revenue for the full year. The quarterly revenue is expected to be in the range of $56.2 to $56.3 million, higher than$49.0 million in the prior year.
U.S.-based preliminary fourth-quarter revenue is expected to be in the range of $53.3 to $53.4 million, up 14% from $46.9 million a year ago.
Cash and equivalents were approximately $147.7 million in the fourth quarter.
For the full year 2025, preliminary revenue is expected to range between $200.8 and $200.9 million, up 20% from $167.18 million in the year-ago period.
Preliminary U.S. revenue for the full year is seen between $190.9 and $191.0 million, up 21% from $158.4 million in the prior year.
Since April 2025, SIBN has traded between $12.50 and $21.89. The stock had closed Monday's trade at $16.27, down 1.27%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.